BioSpace News Archive

New guidelines enhance the ability of veterinarians to assess renal function

Alpine Immune Sciences, Inc. announced planned poster presentations at upcoming scientific meetings highlighting new preclinical data on the Company’s lead programs: ALPN-101, a first-in-class dual CD28/ICOS inhibitor for the treatment of autoimmune diseases, and ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancers.

Heron Therapeutics, Inc. announced positive topline results of a multi-center postoperative pain management study in which 51 patients undergoing total knee arthroplasty (TKA) surgery received the investigational agent, HTX-011, together with a scheduled postoperative regimen of generic, oral analgesics (acetaminophen and celecoxib).

Software integration will help providers augment and extend EHR functionality, driving greater clinician satisfaction

DURECT Corporation announced that the U.S. Food and Drug Administration has notified the Company that its Class 2 NDA resubmission for POSIMIR® will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee.

Verve Therapeutics announced that Sekar Kathiresan, M.D., chief executive officer, will be speaking at the 2019 Jefferies Gene Therapy/Editing Summit.

Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC

Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery

CytoSorbents Corporation announces positive surgical outcomes in a recent publication entitled, “CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding,” in the journal Annals of Thoracic Surgery, ahead of the European Association of Cardio-thoracic Surgery Annual Meeting in Lisbon, Portugal, October 3-5, 2019.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data, which further demonstrates the potential of ibrexafungerp as a treatment for invasive fungal infections, will be presented at IDWeek 2019, occurring October 2-6, 2019 in Washington DC, and TIMM-9, occurring October 11-14, 2019 in Nice, France